.svg)
Conventional tableting processes generate frictional heat, often enough to compromise active pharmaceutical ingredients (APIs) that are thermally labile. In formulations where even moderate increases in temperature alter the physical or chemical nature of the API, traditional manufacturing methods prove inadequate.
This is where Pellet Cold Forming Technology (PCFT) offers a critical advantage, especially in the context of heat-sensitive API manufacturing. Rather than treating heat-induced degradation as a downstream problem to be mitigated with stabilizers or coatings, PCFT addresses the issue at the source during the manufacturing process.
Heat is an invisible disruptor during the process of tablet formation. The mechanical compression during manufacturing generates significant thermal energy. This latent heat can affect both excipients and active pharmaceutical ingredients (APIs), compromising product stability and performance.
In particular, heat-sensitive APIs are vulnerable to degradation, polymorphic transformation, or even the formation of toxic by-products when exposed to elevated temperatures. Traditional tableting methods, especially those involving high compression forces or wet granulation, risk exceeding the thermal thresholds that sensitive molecules can tolerate.
Moreover, certain excipients with low glass transition temperatures (Tg) soften at relatively low heat levels, altering tablet porosity and disintegration characteristics. These changes ultimately impact dissolution rates, critical for drug bioavailability, and challenge batch-to-batch reproducibility.
Pellet Cold Forming Technology (PCFT) bypasses the core issue: heat. By forming pellet formation at controlled, low temperatures, PCFT allows formulating APIs that would degrade or lose potency in conventional systems. It avoids the pitfalls of heat-intensive processes, such as hot-melt extrusion or traditional compression, and ensures the molecular integrity of sensitive compounds from production to patient use.
This technique represents a significant leap in advanced pelletization pharma, providing an alternate approach for developing temperature-sensitive drug development.
PCFT harnesses mechanical energy at ambient or sub-ambient conditions to produce uniform, spherical pellets without subjecting the material to thermal stress. It combines extrusion-spheronization under cooled conditions with controlled moisture and binder systems, balancing plasticity and cohesion without causing heat-induced transformations.
Studies using paracetamol, a common model for thermally sensitive APIs, show that high-temperature compression alters dissolution and disintegration profiles. Elevated temperatures increase polymer mobility near or beyond their glass transition temperature (Tg), which reduces porosity and shifts the release profile toward sustained release. While this effect may benefit certain formulations, it introduces risk for APIs that require immediate release or tight pharmacokinetic control.
Pellet Cold Forming Technology (PCFT) avoids this issue. By forming pellets at controlled, low temperatures, it preserves microstructure, maintains consistent disintegration times, and retains the intended release kinetics throughout processing.
Pelletization has redefined oral drug delivery. Multi-particulate systems, particularly pellets, provide numerous benefits: controlled release profiles, reduced gastric irritation, better bioavailability, and dose flexibility. Their compatibility with capsules, tablets, and sachets enhances patient compliance and market adaptability.
Among various pelletization techniques, cold forming stands apart when dealing with unstable APIs. PCFT allows manufacturers to process delicate molecules without compromising their structure. This makes it ideal for formulating drugs that are prone to hydrolysis, oxidation, or polymorphic shifts, conditions often exacerbated by heat and moisture in standard processes.
API instability is multifactorial i.e., affected by heat, humidity, pH, light, and interactions with excipients. In formulation development process-induced degradation is often observed to can be just as detrimental as long-term storage effects.
Moreover, polymorphic APIs that offer improved bioavailability in specific forms are especially at risk. Heat can induce unwanted transitions to less soluble or inactive forms, nullifying the therapeutic advantage of careful pre-formulation work.
Pellet Cold Forming Technology mitigates this risk by operating below critical transformation temperatures, ensuring that the API retains its designed polymorphic state throughout processing.
For formulations targeting precise and sustained drug release, technologies such as Rapid Gelation Drug Release Technology (RGDRT) offer complementary advantages. RGDRT enables delivery with pseudo-zero-order kinetics, providing a controlled alternative to systems like OROS®. Learn more about how RGDRT enhances bioavailability in this detailed overview.
From a regulatory standpoint, consistency and reproducibility are non-negotiable. Batch failures due to thermal degradation or inconsistent release profiles not only disrupt timelines but also inflate costs and risk product recalls. PCFT can help establish a robust formulation platform that assures performance across scale-ups.
From a commercial perspective, advanced pelletization pharma methods such as PCFT open new possibilities for fixed-dose combinations (FDCs), modified-release therapeutics, and global lifecycle management of complex generics.
By overcoming the temperature barriers that limited certain APIs, the technology can offer an advantage to more niche therapeutic areas and deliver high-performance products that meet modern pharmaceutical needs.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
